Fresenius Kabi is keen for a physical US Food and Drug Administration reinspection at its large-scale sterile injectables plant in Melrose Park near Chicago “sooner rather than later,” after conceding that no product launches from the site are anticipated in 2021.
Last year, an FDA inspection at Melrose Park revealed multiple Form 483 deficiencies, including a failure to properly deal with...






